XML 53 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Hierarchy on Valuation Techniques

The following tables present information about the Company’s derivative liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and October 1, 2024 (Issuance) and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   Fair Value Measurements at October 1, 2024 (Issuance) 
   Quoted Prices in Active Markets for Identical Assets   Other Observable Inputs   Significant Unobservable Inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
Derivative liabilities - warrants  $   $   $19,494,000   $19,494,000 
Total  $   $   $19,494,000   $19,494,000 

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   Fair Value Measurements at December 31, 2024 
   Quoted Prices in Active Markets for Identical Assets   Other Observable Inputs   Significant Unobservable Inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
Derivative liabilities - warrants  $   $   $16,400,000   $16,400,000 
Total  $   $   $16,400,000   $16,400,000 
Schedule of Fair Value of Warrants

The fair value of the warrants was determined using a Black-Scholes pricing model and the following assumptions:

 

   December 31, 2024   October 1, 2024 
Exercise price  $1.9445   $12.00 - $25.00 
Stock price  $3.47   $7.91 
Expected term   4.75    5.00 
Volatility   133.00%   108.00%
Risk-free rate   4.28%   3.45%
Dividend yield   0.00%   0.00%
Probability of capital raise below exercise price   100%   100%
Schedule of Fair Value of Net Asset Value

The initial fair value of the warrant liabilities of $19,494,000 exceeded the net proceeds received in the October 2024 Offering (see Note 9). Therefore, we recognized a loss in equity financing of $15,305,761 comprised of the following:

 

   Amount 
Gross proceeds  $6,466,500 
Less: placement agent and legal fees   (778,261)
Net proceeds   5,688,239 
Less: Series F issued for Alpha consent   (1,500,000)
Less: Fair value of warrant liabilities at Issuance   (19,494,000)
Loss on equity financing  $(15,305,761)
Schedule of Fair Value of Warrant Liabilities

During the year ended December 31, 2024, we recognized a fair value gain on the warrant liabilities of $3,094,000 for the change in fair value between issuance and year end. A reconciliation of the warrant liabilities is below:

 

   Amount 
Balance, beginning of the year  $ 
Warrant liabilities at issuance   19,494,000 
Change in fair value of warrant liabilities   (3,094,00)
Balance, end of the year  $16,400,000